Dupilumab: Direct Cost and Clinical Evaluation in Patients with Atopic Dermatitis
Open Access
- 15 February 2023
- journal article
- research article
- Published by Wiley in Dermatology Research and Practice
- Vol. 2023, 1-6
Abstract
Health care spending in Italy is high and continues to increase; assessing the long-term health and economic outcomes of new therapies is essential. Atopic dermatitis (AD) is a chronic, pruritic, immune-mediated inflammatory dermatosis, a clinical condition that significantly affects patients’ quality of life at a high cost and requires continuous care. This retrospective study aimed to assess the direct cost and adverse drug reactions (ADRs) of Dupilumab and patients’ clinical outcomes. All AD patients treated with Dupilumab at the Sassari University Hospital, Italy, between January 2019 and December 2021 were included. Eczema Area Severity Index, Dermatology Life Quality Index, and Itch Numeric Rating Scale scores were measured. ADRs and drug expenses were analyzed. A statistically significant posttreatment improvement was observed for all the indices measured: EASI ( ), DLQI ( ), NRS ( ). The total expenditure for Dupilumab, in the observed period, amounted to € 589.748,66 for 1358 doses, and a positive correlation was shown between annual expenditure and delta percentage of variation pre- and posttreatment for the clinical parameters evaluated.Keywords
This publication has 14 references indexed in Scilit:
- Mechanisms of DupilumabClinical & Experimental Allergy, 2019
- A review of dupilumab in the treatment of atopic diseasesHuman Vaccines & Immunotherapeutics, 2019
- MONOCLONAL ANTIBODY THERAPIES for Atopic Dermatitis: Where Are We Now in the Spectrum of Disease Management?2019
- Economic Evaluation of Dupilumab for Moderate-to-Severe Atopic Dermatitis: A Cost-Utility Analysis2018
- Economic Evaluation of Dupilumab for the Treatment of Moderate-to-Severe Atopic Dermatitis in AdultsDermatology and Therapy, 2017
- Systemic Treatment of Adult Atopic Dermatitis: A ReviewDermatology and Therapy, 2016
- A review on the role of moisturizers for atopic dermatitisAsia Pacific Allergy, 2016
- Measuring the Value of Prescription DrugsNew England Journal of Medicine, 2015
- Progressive activation of TH2/TH22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitisJournal of Allergy and Clinical Immunology, 2012
- Management of Patients with Atopic Dermatitis: The Role of Emollient TherapyDermatology Research and Practice, 2012